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Abstract
The prevalence of chronic hepatitis B and C virus infection has declined among the
dialysis population during the past decades. However, it still comprises a major health
problem  with  high  morbidity  and  mortality.  Renal  transplantation  is  the  optimal
treatment for patients with end‐stage renal disease and hepatitis B or C, although it is
associated to lower patient and allograft survival compared to seronegative kidney
recipients. Novel therapeutic strategies with the use of new antiviral agents, especially
direct‐acting antiviral  agents in hepatitis  C,  have significantly changed the natural
history of both hepatitis B and C not only in the general population but also in renal‐
transplant recipients. We believe that future research should focus on the impact of new
antiviral medications in this specific subset of patients.
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1. Introduction
Though the prevalence of both hepatitis B and C is decreasing at least in developed countries,
it still ranges from 0.1 to 20% for hepatitis B and from 2.5 to 13% for hepatitis C. General hygiene
measures as well as specific measures in dialysis units and vaccination programs contributed
to the reduction of hepatitis B and C prevalence in the dialysis population. However, hepatitis
B and C seropositivity still remain an important clinical problem in this patient population
associated with a high risk of morbidity and mortality. Although kidney transplantation is the
treatment of choice for hepatitis B‐ and C‐infected dialysis patients, morbidity and mortality
are worse compared to seronegative patients. Major causes of death are liver cirrhosis and
hepatocellular carcinoma.
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This review focuses on pretransplant and posttransplant evaluation of prospective donors and
recipients emphasizing the optimal use of grafts from hepatitis B‐ or C‐seropositive donors
and the impact of hepatitis B or C infection in patient and allograft survival. Additionally, it
focuses on the role of novel antiviral agents.
2. Kidney transplantation and hepatitis B virus infection
2.1. Epidemiology
The human hepatitis B virus (HBV) is a small enveloped DNA virus causing acute and chronic
hepatitis. Although a safe and effective vaccine has been developed and it has been available
for the last two decades, HBV infection still represents a major global health problem. It is
estimated that approximately 30% of the world's population has had contact with or are
carriers of the HBV. An estimated 350 million of them are HBV carriers [1]. Around one million
persons die of HBV‐related causes annually. HBV prevalence varies from 0.1% in Western
Europe, United States, Canada, Australia, and New Zealand, up to 20% in southern Asia,
China, and sub‐Saharan Africa. Intermediate prevalence (3–5%) is the Mediterranean coun‐
tries, Japan, Central Asia, the Middle East, and South America. Acute infection occasionally
results in fulminant hepatitis, but more importantly can progress to a chronic state, with
decompensation, cirrhosis, and hepatocellular carcinoma being the most serious complica‐
tions. The progression rate is approximately 90% for an infection acquired perinatally, and
decreases to 5% for infections acquired during adulthood [2].
Hemodialysis (HD) patients are at an increased risk of acquiring HBV. Reasons include
increased exposure to blood products, shared hemodialysis (HD) equipment, breaching of
skin, and immunodeficiency. Hemodialysis, which requires access to the bloodstream, also
may favor transmission of HBV between patients, and between patients and staff.
The prevalence of hepatitis B virus infection in hemodialysis patients has significantly
decreased over the past few years. This is due to the implementation of effective prevention
measures, such as general hygiene rules, separation during hemodialysis, and hepatitis B
vaccination. The most important measure to prevent HBV infection is immunization against
the virus. Chronic dialysis patients should receive vaccination against hepatitis B. Ideally,
patients with chronic kidney disease (CKD) should receive vaccination against hepatitis B at
earlier stages of the disease, before starting dialysis, since vaccine immunogenicity is low in
dialysis patients (70%) compared to 90% in the general population. Intensified vaccination
protocols have been used in hemodialysis patients with good responses. The presence of an
adequate hepatitis B antibody (anti‐HBs) titer should be checked annually. If the antibody titer
is lower than 10 IU/ml, a booster dose of the vaccine should be administrated [3].
Although rates of new infection are decreasing [4], hepatitis B still remains a problem in
dialysis populations. According to data from the United States Renal Data System (USRDS) in
2002, 1% of dialysis patients were seropositive for HBsAg [3]. A registry study of Asia‐Pacific
countries found the prevalence of hepatitis B surface antigen (HBsAg) positivity ranging from
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1.3 to 14.6% [5]. Despite the decrease of HBsAg prevalence in dialysis patients, 350 million
people worldwide are chronic HBV carriers and a large number of them will need transplan‐
tation in the future [6].
Hepatitis B virus–infected patients are at risk of exacerbation of the infection, progressive liver
disease, and development of hepatocellular carcinoma after kidney transplantation. Renal
transplantation offers higher survival and better quality of life compared to hemodialysis,
which also applies to HBV patients, providing that they are receiving antiviral prophylaxis,
since it is easier to prevent than treat HBV reactivation [7].
2.2. Evaluation of HBV‐infected dialysis patients before transplantation
All dialysis patients should be checked routinely for HBsAg and when indicated with HBV
DNA. HBV infected kidney transplant candidates should be tested for hepatitis B e antigen
(HBeAg) and serum HBV DNA prior to transplantation. Patients who are HBeAg positive or
have high levels of HBV DNA should receive antiviral treatment before transplantation with
one of the available agents (lamivudine (LAM), entecavir (ETV), adefovir, tenofovir, and
telbivudine (LdT)) until HBeAg becomes negative and viral replication is suppressed.
According to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines, it is
recommended that a liver biopsy is performed in HBsAg‐positive hemodialysis patients on
the waiting list for transplantation in order to evaluate liver disease status. If there is ongoing
viral activity, candidates should repeat liver biopsy every 3–5 years [8]. Noninvasive testing
for liver stiffness as fibroscan (elastography), which tends to replace liver biopsy in the general
population, has not yet been validated neither in HBV‐positive patients nor in patients on
hemodialysis or after transplantation [9]. So, liver biopsy while on the waiting list still remains
the “gold standard” for kidney transplant candidates.
Liver cirrhosis has for long been considered as an absolute contraindication for kidney
transplantation alone; combined liver kidney transplantation is the treatment of choice in these
patients. However, with the use of new nucleos(t)ide analogs, some dialysis patients with
compensated cirrhosis achieve sustained viral response (SVR). If a follow‐up biopsy after 12
months reveals partial reversibility of cirrhosis, those patients can be after that included in the
waiting list and undergo kidney transplantation alone. This has been reported for HBV‐ and
hepatitis C virus (HCV)‐positive patients after SVR with the new antivirals [10].
HBsAg‐positive renal transplant candidates should start antiviral treatment immediately after
transplantation, regardless of the HBV DNA status or the findings of liver histology, due to
the risk of severe reactivation, fibrosing cholestatic hepatitis, and rapid histological deteriora‐
tion after the induction of immunosuppression.
2.3. Transmission of HBV infection from the donor
Besides HBV reactivation, HBV may be transmitted from the donor to the recipient. Renal
transplantation from HBsAg‐positive donors to HBV‐naïve recipients is not recommended
because it carries a significant risk of de novo infection, most often with an aggressive course
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[11]. On the other hand, as shown by Jiang et al., allografts from HBsAg‐positive donors can
safely be transplanted into HBsAg‐negative recipients with natural or acquired immunity
(anti‐HBs positive, titer above 10 IU/ml), with concurrent administration of hepatitis B
hyperimmune globulin (HBIG) with or without booster vaccination [12]. In such cases,
although the risk of transmission is relatively low, it is mandatory to inform patients and to
obtain written consent in order to proceed with kidney transplantation. In a study by Singh et
al., the successful procedure was described in 104 anti‐HBs–positive recipients [13]. Prevention
strategies included booster vaccination and concomitant administration of HBIG in combina‐
tion with antiviral agents while vaccination alone was used in 27 patients.
In our center, we perform kidney transplantations from HBsAg‐positive donors to HBsAg
negative/HBsAb positive, that is, immunized either from past infection or from vaccination
recipients. Those transplantations are performed only if the antibody titer of the recipient,
measured immediately before transplantation, is at least 10 IU/ml and with concomitant
administration of one dose of booster vaccination in combination with hepatitis B hyperim‐
mune globulin(HBIG) while most of the recipients are started on antiviral prophylaxis
postoperatively. The need and the duration of antiviral treatment in this patient population
have not been investigated; moreover, data about monitoring long term are lacking. It seems
logical to assume that antibody titer should be checked and booster vaccination should be
administered when the titer falls below 10 IU/ml, since transplant recipients receiving
immunosuppression are at risk for viral reactivation—if it has been transmitted from the donor
—for long. However, to the best of our knowledge, current evidence is so sparse that only
suggestions can be made.
Another issue regarding donor to recipient HBV transmission is that there is a very low but
substantial risk of HBV transmission from HBsAg‐negative, anti‐HBc‐positive, anti‐HBs–
negative donors to HBV‐naïve recipients. In a recent review of 1385 HBsAg‐negative kidney
recipients from anti‐HBc–positive donors, seroconversion to HbsAg positivity occurred in
0.28% (4/1385) and to anti‐HBc positivity in 2.3% (32/1385) [14–16]. Ideally, those donors should
be checked for anti‐HBc IgM presence, indicating a more recent infection rather than ineffective
immune response. Unfortunately, in the case of transplantation from deceased donors, this is
impossible, due to the shortness of time. Given the organ shortage and the survival advantage
of transplantation over remaining on hemodialysis, kidney transplantation could be consid‐
ered in these cases too, since the risk for transmission is even lower than from HBsAg‐positive
donors. Again without data supporting the evidence, one may suggest that, in this case too,
transplant candidates should be immunized and receive prophylaxis with booster vaccination
and HBIG administration, while antiviral prophylaxis may not be indicated in this setting.
2.4. Outcome of HBV‐infected patients after kidney transplantation
HBV‐infected renal allograft recipients have worse survival compared to their seronegative
counterparts. A meta‐analysis of six observational studies, which included 6050 HBsAg‐
positive patients after kidney transplantation, showed that the relative risk of death and graft
loss were 2.49 and 1.44, respectively [17].
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The widespread use of antiviral agents since 1986 has significantly improved survival of HBV‐
infected kidney transplant recipients. In a small study from Italy, 42 HbsAg‐positive patients
who have been transplanted between 1976 and 1982 had a 12‐year survival rate of 67% [18]. In
a more recent study from Hong Kong, a 10‐year survival of 63 HbsAg‐positive renal transplant
recipients who were treated with nucleoside/nucleotide analogs reached 81% [19]. However,
liver failure remains the leading cause of death in this patient population. HBsAg‐seropositive
recipients who are HBeAg‐negative have undetectable viral load, and for mild changes in liver
biopsy they should receive preventive antiviral therapy immediately posttransplantation, in
order to avoid viral reactivation due to immunosuppressive therapy. The only study that
evaluated serial biopsies after kidney transplantation found histological deterioration in 85%
of HBsAg‐positive patients. No patient had cirrhosis before kidney transplantation while 28%
of them had biopsy‐proven liver cirrhosis after transplantation. Among those with cirrhosis,
hepatocellular carcinoma was found in 23% [20].
2.5. Antiviral agents
The goal of treatment is suppression of viral replication and prevention of hepatic fibrosis,
while minimizing resistance to the drugs. HBV DNA levels need to be measured systematically
to assess response to therapy, because of the poor likelihood of seroconversion to anti‐HBs and
because of low reliability of alanine aminotransferase (ALT) as a marker of liver disease activity.
Treatment must be initiated before or immediately after transplantation. In a study of 15
patients, seven were started on lamivudine at the time of kidney transplantation. All patients
had normal transaminase levels preoperatively. Half of those who were not treated initially
showed transaminase elevations in the first year of follow‐up requiring lamivudine therapy
at that time. By contrast, all seven individuals who had received lamivudine at the time of
transplantation remained negative for HBV DNA throughout the follow‐up [21].
Currently, there are several medications available for the treatment of hepatitis B: interferon
alfa‐2b, pegylated interferon (PEG‐INF) alfa 2a, and the nucleos(t)ide analogs lamivudine,
adefovir, tenofovir, telbivudine, and entecavir.
2.5.1. Interferon and PEG‐INF
In the current era of potent antiviral drugs as nucleoside analogs, the use of interferon‐α (IFN)
and PEG‐IFN after transplantation is not recommended anymore. IFN‐α has known immu‐
nomodulatory effects and its use in case series of kidney transplant recipients in the past has
been associated with increased rates of graft loss due to rejection and with relapse rates
approaching 80% after therapy discontinuation [22].
2.5.2. Lamivudine (LAM)
Lamivudine is a cytosine analog that inhibits HBV reverse transcriptase. The prophylactic use
of lamivudine posttransplantation has proven efficacy long term. Since LAM was the first
nucleoside analog approved for clinical use, most of the available data on the management of
HBsAg‐positive renal transplant recipients are with this agent. A meta‐analysis of 14 clinical
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studies, which included 184 patients, showed that LAM administration results in undetectable
viral load in 91% and a normalization of alanine aminotransferase (ALT) in 81% of patients,
for a prolonged period of time [23]. Lamivudine has for long been the cornerstone of therapy
in HBV‐infected kidney transplant recipients and has increased survival rates. HBsAg‐positive
kidney recipients treated with lamivudine reached 10‐year survival rates of 81%, comparable
to HBsAg‐negative patients [24].
Since it is eliminated by the kidney, its dose should be adapted to renal function: recommended
dose is 100 mg/day in patients with estimated glomerular filtration rate (eGFR) >50 ml/min
and 100 mg every other day in patients with less‐preserved renal function.
The major problem with prolonged lamivudine treatment is the development of resistance.
The presentation of the resistance varies. Some patients show only reappearance of serum HBA
DNA, while others present with elevated liver enzymes. In most cases, resistance occurs due
to a mutation in the tyrosine‐methionine‐aspartate‐aspartate (YMDD) locus of the HBV DNA
polymerase [25].
In a series of studies, the rates of lamivudine resistance vary from 20 up to 60% [26, 27]. In a
study of 29 renal transplant recipients, after a mean follow‐up of 69 months, 14 patients (48%)
developed lamivudine resistance. Among them, 79% presented with a hepatitis flare. The
YMDD mutation was found in all cases of resistance [25]. A meta‐analysis of 2004 showed that
increased duration of lamivudine therapy was positively associated with lamivudine resist‐
ance [22].
Patients with lamivudine resistance should be treated with adefovir, tenofovir, entecavir, or
telbivudine.
2.5.3. Tenofovir disoproxil fumarate (TDF)
Tenofovir disoproxil fumarate (TDF) is a nucleotide analog and a potent inhibitor of human
immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus polymerase.
Tenofovir is a potent antiviral agent for treatment‐naïve patients and for patients with
lamivudine resistance [28, 29]. Data for patients who have undergone kidney transplantation
are limited and there are concerns for the development of kidney injury. Daude et al. conducted
a study, which showed effective suppression of viral replication after 12 months of follow‐up
and preservation of stable kidney function in seven hepatitis B virus‐positive solid‐organ
transplant recipients, with three renal‐transplant recipients among them [30]. In a study of
patients from the general population with HBV infection, tenofovir was effective in lamivu‐
dine‐resistant cases, and did not induce resistance after up to 48 months of treatment [31].
2.5.4. Telbivudine (LdT)
Telbivudine is not effective in kidney transplant recipients with lamivudine‐resistant HBV,
because it shows cross‐resistance to lamivudine and entecavir, since the virus develops the
same mutations for both medications. Data about the use of telbivudine in renal transplanta‐
tion are lacking.
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2.5.5. Entecavir (ETV)
Entecavir, a guanosine analog, is 30 times more potent than lamivudine in suppressing viral
replication and nowadays it is used as first‐line prophylactic treatment in renal transplant
recipients. This drug has a high antiviral potency, a high genetic barrier for resistance, and a
good safety profile. There is sufficient evidence that it can effectively clear the viral load for a
prolonged period. A recent prospective study included 27 renal transplant recipients, 18 (67%)
were treatment naïve and 9 (33%) had been previously treated with LAM but had no resistant
mutations. Entecavir cleared HBV DNA in 70, 74, 96, and 100% of patients after 12, 24, 52, and
104 weeks, respectively. Furthermore, entecavir reached higher rates of undetectable HBV
DNA compared to lamivudine (32, 37, 63, and 63% at 12, 24, 52, and 104 weeks, respectively;
P < 0.005) [32]. However, in patients with lamivudine‐resistant HBV, complete response to
entecavir can be delayed for more than 6 weeks, or not be achieved at all. The use of entecavir
in renal transplant recipients who had developed lamivudine—or adefovir—resistance has
been examined in a small study of 10 solid‐organ‐transplant recipients, with 8 kidney‐allograft
recipients among them, who were treated with entecavir for 16.5 months. There was a
significant decrease in HBV DNA viral load (50%) without any significant adverse events [33].
Resistance to entecavir has not been documented in renal transplant recipients. In the general
population, the rate of entecavir resistance is minimal (1.2%) in treatment‐naïve patient after
5 years of therapy. However, in lamivudine‐resistant patients, the probability of entecavir
resistance at years 1–5 rises from 6 to 15, 36, 46, and 51%, respectively [34].
2.5.6. Adefovir dipivoxil (ADV)
Adefovir is an acyclic nucleotide adenosine analog. Adefovir is effective as monotherapy or
in combination with entecavir in the general population with HBV infection and lamivudine
resistance [35–38]. The problem with this agent is that it is potentially nephrotoxic. Studies in
human immunodeficiency virus (HIV) patients show that high daily doses of adefovir (60–120
mg) may cause renal tubular injury. The drug is mainly used in lamivudine‐resistant HBV
cases [39]. Fontaine et al. studied the efficacy of adefovir as monotherapy at 11 renal‐transplant
recipients with lamivudine resistance. After 12 months, a satisfactory decline in serum HBV
DNA and an absence of hepatitis flares were observed. Importantly, there were no significant
clinical and laboratory adverse events [35]. In another study of 11 renal‐transplant recipients
with lamivudine resistance, adefovir was given at very low doses (10–2.5 mg/day) and it
showed good efficacy, without nephrotoxicity [38]. In another study, evidence of nephrotox‐
icity implementing treatment discontinuation despite dosage adjustment was observed in 29%
of patients [39].
2.6. Treatment duration
In the general population, the duration of treatment depends on the HBeAg status. HBeAg‐
positive patients should be treated until HBV DNA and HBeAg are cleared and anti‐HBe
seroconversion occurs. Additional treatment is needed for at least 6–12 months after anti‐HBe
seroconversion to prevent virological reactivation. Patients without HbeAg should be treated
until HBsAg clearance. The duration of antiviral therapy for renal transplant recipients
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remains unclear, because outcomes after nucleos(t)ide analogs withdrawal in immunosup‐
pressed patients allograft recipients are unknown.
One small retrospective study [40] evaluated the course of 6 out of 14 HBsAg(+) kidney‐
transplant recipients, in whom antiviral treatment had been discontinued after a median of 14
months. All of the six patients in whom antiviral agents had been discontinued were on stable,
low‐dose maintenance immunosuppression with undetectable HBV DNA and serological
negativity for HBeAg. In four out of the six patients (67%), antiviral withdrawal was successful,
without any sign of reactivation after a median follow‐up of 60 months. In the remaining two
patients, who had reactivated HBV, antiviral therapy was reintroduced immediately, with
subsequent HBV clearance. Though the number of patients is indeed small, the study provides
promising results for future investigation.
In the absence of robust data, we can suggest that antiviral treatment after kidney transplan‐
tation may be discontinued only in a subset of carefully selected patients who meet the
following criteria: stable renal function and low immunological risk for rejection, low‐dose
maintenance immunosuppression for at least 6–9 months, no serological or biochemical
evidence for HBV activity and previous antiviral treatment without resistance to any antiviral
agent for at least 12 months. Close monitoring of HBV DNA every 3–6 months is essential,
while antivirals should be reintroduced whenever immunosuppression must be intensified,
that is, in the case of anti‐rejection treatment.
2.7. Reactivation of HBV after renal transplantation: the role of immunosuppression
Immunosuppression is associated with hepatitis B virus reactivation not only in HBsAg‐
positive recipients but also in patients seropositive for anti‐HBc/anti‐HBs, usually in low titers,
that is, past infection (reverse seroconversion) [41].
The majority of data come from studies in HBV patients treated for solid‐organ or hemato‐
logical malignancies [41, 42].
The main factors associated with HBV reactivation posttransplantation are the immunocom‐
petence of the recipient, the total amount of immunosuppression, and finally the characteristics
of the virus.
The status of immunosuppression changes the interaction between the HBV virus and the host,
leading to potentially severe liver injury. Liver damage in the setting of immunosuppression
may occur through two different mechanisms. The first mechanism is direct hepatotoxicity
after the introduction of immunosuppression due to uncontrolled viral replication as a
consequence of reduced immunosurveillance of the host. The second mechanism involves
indirect, immune‐mediated liver damage occurring after cessation of immunosuppression,
during immune reconstitution. The second mechanism has been described in patients with
solid‐organ or hematologic malignancies even up to 6–12 months after completion of chemo‐
therapy [43].
Since renal transplant recipients receive lifelong immunosuppression, hepatotoxicity in this
setting may mostly be attributable to the first mechanism with the highest risk for viral
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reactivation being during the induction period, when the total amount of immunosuppression
is high or whenever immunosuppression is intensified after that, as, for example, during anti‐
rejection treatment.
2.8. Immunosuppressive agents
Corticosteroids (CSs), calcineurin inhibitors (CNIs) (cyclosporine and tacrolimus), antimeta‐
bolites (mycophenolate mofetil (MMF) or mycophenolic sodium and azathioprine), and
mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus) are the main
immunosuppressants used in various combinations in kidney transplantation. Monoclonal
antibodies (Rituximab, anti‐IL2 Basiliximab) and polyclonal antibodies as antithymocyte
globulin (ATG) are also part of the immunosuppressive regimen used for the induction or for
the treatment of rejection. All of them are implicated in alterations of viral replication, mostly
by inducing increased viral replication and enhance the risk of HBV reactivation. The risk of
HBV reactivation according to specific immunosuppressive drug classes has been estimated
by the American Gastroenterological Association (AGA) [44].
2.8.1. Rituximab
According to the AGA guidelines, Rituximab has the highest risk estimate of HBV reactivation
(high >10%) from all immunosuppressants used in kidney transplantation. Moreover, the risk
of HBV reactivation may persist up to 12 months, since the antibody has a prolonged phase of
immune reconstitution.
Rituximab administration has been associated with HBV reactivation not only in HBsAg‐
positive but also in anti‐HBc–positive and anti‐HBs–positive patients (reverse seroconversion).
In a prospective study of 314 HBsAg‐negative patients with B‐cell lymphoma treated with
Rituximab, 16.2% were HBV carriers. All of them were anti‐HBc positive, whereas half of them
were also anti‐HBs positive. Virus reactivation occurred in 12% of patients. HBV DNA
clearance with the use of entecavir permitted readministration of Rituximab [45].
2.8.2. Polyclonal antibodies (antithymocyte globulin, ATG)
Increased viral replication following ATG administration has been described for herpes
viruses, Epstein‐Barr virus (EBV), and, to a lesser degree, cytomegalovirus (CMV). In those
cases, ATG has been administered to patients with severe aplastic anemia concomitantly with
cyclosporine [46]. Data about HBV reactivation after treatment with ATG are lacking.
2.8.3. Corticosteroids (CS)
Corticosteroids are the oldest and commonest immunosuppressants worldwide. Its use is
undoubtedly associated with increased viral replication. Since they are used in many dosages,
the risk of HBV reactivation depends on the dose and duration of CS administration. High
corticosteroid doses increase viral replication, while ALT may be decreased. The opposite is
observed during steroid tapering with elevated aminotransferases 4–6 weeks after steroid
discontinuation [40]. According to the AGA guidelines, high CS doses (up to 20 mg/d of
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prednisone) and/or prolonged (>3 months) administration are considered as high risk for HBV
reactivation while rapid tapering may also increase the risk for viral reactivation due to
immune reconstitution.
In kidney transplantation, high CS doses are administered during the first weeks post
transplantation; thereafter, they are tapered during a period of 3–6 months to a maintenance
dose of 5 mg of prednisone daily or every other day. In stable, low‐immunological risk patients
they may be avoided completely (steroid‐avoidance protocols) or they may be withdrawn after
4–6 weeks or even later (steroid‐withdrawal protocols) with excellent outcomes. High CS
doses, including intravenous pulses of methylprednisolone up to 500 mg/d, are used for the
treatment of acute rejection.
In HBV kidney transplant recipients, steroids must be used at the lowest possible doses and
preferably be discontinued or even completely avoided in patients with low immunological
risk.
2.8.4. Calcineurin inhibitors
Calcineurin inhibitors are still the cornerstone of immunosuppression in kidney transplanta‐
tion. It has been shown that cyclosporine reduces viral replication in vitro. Nowadays, most
immunosuppressive regimens are tacrolimus based. Although there are no definite conclu‐
sions or guidelines, some suggest that cyclosporine may be preferable to Tacrolimus in HBV
kidney transplant recipients. Nevertheless, since there are no definite conclusions, the choice
of one of the two calcineurin inhibitors depends on the center's practice. Some others may
argue that it is easier to withdraw steroids from a Tacrolimus‐based regimen and would prefer
this choice [47, 48].
2.8.5. Antimetabolites
Azathioprine, though hepatotoxic per se, has not been associated with an increased risk of
HBV reactivation when given as monotherapy. Nevertheless, after the introduction of the more
selective and more potent antimetabolites as the mycophenolic acids (MPAs), the use of
azathioprine in kidney transplantation has been restricted to patients with special indications
[49].
2.8.5.1. Mycophenolate acid derivates
Mycophenolate mofetil and the newer mycophenolate sodium have nowadays replaced
azathioprine in most immunosuppressive regimens. Data about MPAs and HBV reactivation
are lacking, but in general they are considered safe for HBV kidney‐transplant recipients.
2.8.6. Mammalian target of rapamycin (mTOR) inhibitors
The reactivation of HBV with the use of mTOR inhibitors has not been studied in renal‐
transplant recipients and generally they are considered safe. Some case reports of HBV
reactivation related to everolimus when used as a chemotherapeutic agent have been reported
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but everolimus dosage in this setting is much higher than the usual doses given as maintenance
immunosuppression in kidney transplantation [50].
In conclusion, all immunosuppressants given in kidney transplantation can be used in HBV‐
positive recipients. The most important issue is the total amount of immunosuppression long
term. It is crucial to maintain the lowest level of immunosuppression that is necessary to
prevent rejection and to closely monitor the HBV status. Prophylactic antiviral treatment
should be initiated immediately after transplantation and continued at least for 1 year after
stable and low maintenance immunosuppression. In the carefully preselected patients in
whom antivirals may be discontinued, close monitoring for HBV reactivation is mandatory.
2.9. In summarizing the existing evidence about kidney transplantation and HBV
• Though decreasing, HBV still remains a considerable problem in dialysis patients and
kidney transplant recipients.
• Chronic kidney disease patients should be vaccinated before the initiation of dialysis.
• Intensified vaccination protocols should be applied to hemodialysis patients and antibody
titer checked regularly.
• HBV‐positive dialysis patients need monitoring with HBV DNA, viral serology (including
HBeAg), and liver enzymes.
• HBsAg‐positive candidates for kidney transplantation should be evaluated thoroughly with
HBV DNA, liver enzymes, and liver biopsy.
• Antiviral treatment with tenofovir or entecavir (preferably to lamivudine) should be
introduced to HBsAg‐positive patients with viral activity on the waiting list.
• Patients with decompensated cirrhosis are candidates for combined liver‐kidney transplan‐
tation, while compensated cirrhosis is no more an absolute contraindication for kidney
transplantation alone.
• Kidney transplants from HBsAg‐positive and from HBsAg‐negative/anti‐HBc–positive
donors can be safely transplanted into immunized, HBsAg‐negative recipients with
concomitant prophylaxis.
• HBsAg‐positive kidney transplant recipients should receive antiviral prophylaxis immedi‐
ately after transplantation.
• In the current era of new antivirals, outcomes after transplantation are improving and long‐
term patient and graft‐survival rates are approaching those of HBsAg‐negative‐matched
recipients.
• The duration of antiviral prophylaxis after transplantation is unknown.
• Antivirals can be withdrawn in subsets of patients after transplantation.
• All immunosuppressants can be used in HBsAg‐positive recipients.
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• The total amount of immunosuppression must be kept at the lowest possible levels for the
given donor/recipient.
In conclusion, with growing knowledge and evolving evidence in both fields, hepatitis B and
transplantation, in the era of potent antivirals as nucleoside analogs, HBsAg‐positive kidney‐
transplant candidates and recipients can be successfully treated and monitored and reach
survival rates comparable to their HBsAg‐negative counterparts.
3. Kidney transplantation and hepatitis C virus infection
3.1. Epidemiology of hepatitis C virus (HCV) infection
The prevalence of hepatitis C virus (HCV) infection worldwide is 3% and infected people are
estimated to be approximately 170 millions. Prevalence rates in Africa, America, Europe, and
South‐East Asia are less than 2.5%. In the Western Pacific regions, the prevalence ranges
between 2.5 and 4.9% while in some parts of the Middle East, it reaches 13% [51–53].
The prevalence of hepatitis C in patients with end‐stage renal disease (ESRD) presents great
variation worldwide. In northern Europe, it is below 5%, whereas in the US and southern
Europe, it stands at 10%. In several North African, Asian, and Latin American countries, the
relative disease prevalence varies between 10 and 70% [54]. In Greece, a 2003 collaborative
study of the Hellenic Center for Infectious Diseases Control and the Hellenic Society of
Nephrology showed that the percentage of patients with hepatitis C was 7.5% in a total of 7016
patients on dialysis [55].
Prior to 1990, the main routes of HCV transmission were blood‐product transfusions, intra‐
venous drug use, and unsafe medical procedures. Since the systematic screening of blood
products, the risk of HCV infection related to transfusions is extremely low (1/20000000) [56].
Currently, the main routes of HCV infection are intravenous drug use, unsafe medical
procedures, mother‐to‐child transmission, and the use of unsterilized materials in activities
such as acupuncture and tattooing. Household and sexual transmission is extremely low. The
dialysis‐related risk is estimated at 2% per year. With the screening of blood products and the
use of erythropoiesis‐stimulating agents, the risk of transfusion‐related HCV infection in
dialysis patients has dramatically declined; however, they continue to comprise a “high‐risk”
group. In several studies, the prevalence of HCV infection correlated strongly with the time
on dialysis, independently of the burden of transfusions and it was higher in HD than in home
HD or peritoneal dialysis patients. These data strongly suggest that nosocomial transmission
is of major importance [57].
Therefore, the KDIGO workgroup for the prevention of HCV transmission in dialysis patients
focused on the implementation of hygienic precautions regarding the staff of HD units and
the sterilization of the dialysis machines. Of major importance is the fact that the isolation of
HCV‐infected patients does not seem to protect against HCV transmission in HD units and
therefore it is not recommended [53].
Advances in Treatment of Hepatitis C and B228
4. Kidney transplantation versus dialysis for HCV‐infected dialysis
patients
A meta‐analysis of observational studies tried to establish the impact of hepatitis C virus
infection on survival in dialysis patients. It showed that HCV‐positive patients on dialysis have
an increased risk of mortality compared with their HCV‐negative counterparts, which is
mainly attributed to liver‐associated disease and its complications (relative risk, 5.89) [58].
Kidney transplantation is the treatment of choice for HCV‐positive patients with ESRD. Three
retrospective studies showed that transplantation offered a survival advantage in HCV‐
seropositive patients compared to those who remained on the waiting list [59–61]. A recent
systematic review that included 9 studies with a total number of 2274 HCV‐infected renal‐
transplant candidates and recipients showed that 5 years posttransplantation, anti‐HCV–
positive patients who had undergone kidney transplantation had approximately 55% lower
risk of death compared to wait‐listed patients [62].
5. Diagnosis and assessment of liver disease in HCV‐positive kidney‐
transplant candidates
The clinical tools that are used for the assessment of liver damage for patients with ESRD do
not differ from those used for the general population. Several studies have shown that
aminotransferase (AST, ALT) levels are low in patients on dialysis and this reduction appears
to occur in patients with advanced chronic kidney disease even before the initiation of renal‐
replacement treatment [63, 64].
All patients on the waiting list for a kidney allograft should be tested for hepatitis C, initially
with an anti‐HCV enzyme‐linked immunosorbent assay (ELISA) and after a positive result by
polymerase chain reaction assay (PCR) for the quantification of HCV RNA. Identification and
classification of HCV genotype should follow. Screening for HCV must be a clinical routine
and it must be performed once a year in all dialysis patients, since they are at constant risk of
acquiring HCV infection. Dialysis units with a high prevalence of HCV should adopt a more
strict protocol by examining their patient population for the presence of viremic activity,
regardless of the result of the ELISA test [53].
Liver biopsy is recommended by the KDIGO guidelines as the “gold standard” for assessing
the severity of hepatic damage and the prognosis of the disease. Furthermore, it can provide
valuable assistance in planning the future treatment strategy [65]. A study on percutaneous
liver biopsy in chronic hepatitis C patients found the procedure to be safe without increased
risk in patients with ESRD [66]. The necessity of a liver biopsy is underlined by the following
factors:
• There is no reliable correlation between the fluctuation of aminotransferases levels or the
measurements of HCV RNA and the severity of liver injury as shown by histological
findings in this group of patients [67].
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• The percentage of HCV‐positive renal transplant recipients that develop liver disease in the
course of transplantation varies in different studies between 19 and 64% [59, 60].
• Studies have shown that up to 25% of ESRD patients with chronic hepatitis C infection have
subclinical pre‐cirrhotic disease in liver biopsy [68].
• The finding of advanced fibrosis in liver biopsy is a contraindication for renal transplanta‐
tion, because 10‐year survival is lower than 26% [52]. Patients with adequately compensated
hepatic disease should be referred for simultaneous liver‐kidney transplantation.
Novel, noninvasive, simple radiographic and serologic tests are used to validate hepatic
fibrosis. Transient elastography (TE) evaluates the severity of fibrosis by liver‐stiffness
measurement. It has been used in non‐uremic patients for the staging of fibrosis with satis‐
factory results [69]. In the dialysis population with chronic HCV infection, TE, performed with
a Fibroscan machine, seemed to be efficient in estimating fibrosis in one study available [70].
Aspartate aminotransferase‐to‐platelet ratio index (APRI) is a serologic marker of fibrosis, easy
to calculate. APRI is useful in diagnosing the degree of fibrosis [71], although it has a lower
diagnostic accuracy than TE especially in cases of cirrhosis, in HD as well as in non‐uremic
patients with HCV [70]. Larger cohort studies are needed before noninvasive techniques can
replace liver biopsy. Nevertheless, they can be useful when the biopsy cannot be performed
because of contraindications or patient refusal.
6. Kidney donation from HCV‐positive donors
All prospective donors should be evaluated for the risk of HCV infection based on blood tests,
medical history, and lifestyle habits. Prior to transplantation, deceased and living donors
should be screened for anti‐HCV antibodies, preferably using ELISA third generation.
However, the presence of antibodies against HCV in the donor may indicate a previous cleared
infection and nontransmissibility. Thus, conducting PCR for HCV RNA is the next step for
anti‐HCV–positive donors. In the setting of cadaveric kidney transplantation, the results of
HCV RNA will be available after transplantation. Therefore, the KDIGO guidelines advise
against transplantation from HCV‐positive donors to HCV‐negative recipients [53], since it is
well established that hepatitis C can be transmitted by solid‐organ transplantation with a high
frequency that approaches 100% in some studies [72, 73]. Viral transmission results in the
occurrence of liver disease in the immunocompromised recipient, leading eventually to poor
clinical outcomes due to infectious complications, development of cholestatic syndrome, and
progression to hepatic failure [74].
Allocation of HCV‐positive kidneys is controversial. The strategy of many transplant centers,
including ours nowadays, is to accept kidneys from HCV‐positive‐deceased donors for HCV‐
positive‐transplant candidates. According to the latest KDIGO guidelines [53], seropositive
recipients should be tested by PCR for HCV RNA and must have an active viremia. This
practice is based on the fact that kidney transplantation of HCV‐infected dialysis patients from
HCV‐positive donors reduces the time in the transplant waiting list and is associated with
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superior survival compared to those who remain on the list waiting for a seronegative donor
[75]. Additionally, a retrospective study by Morales et al. examined the differences between
HCV‐positive recipients who were transplanted either from HCV‐positive donors or from
HCV‐negative donors. In terms of decompensated liver disease, no differences were observed
between the two groups (10.3 vs. 6.2%). Moreover, 5‐ and 10‐year patient survival were similar
in the two groups, namely 84.8 and 72.7% in the subset of recipients from HCV‐positive donors
versus 86.6 and 76.5%, respectively, in those who received an HCV‐negative renal allograft.
Five‐ and ten‐year graft survivals were decreased in the HCV‐positive donor group (58.9% at
5 years and 34.4% at 10 years) compared to the HCV‐negative donor group (65.5% at 5 years
and 47.6% at 10 years, p: 0.006). However, this difference was not associated to HCV seropo‐
sitivity in the multivariate regression analysis [76]. Ideally, donors and recipients should be
matched for HCV genotype to minimize the risk of super‐infection, even if this procedure is
rarely performed during a deceased donor evaluation. However, two retrospective studies
showed that the number of HCV genotypes has no significant effect on patient survival [77,
78]. In the new era of HCV treatment with the direct‐acting antiviral agents (DAAs), the
knowledge of the donors’ genotype will be useful for the assessment of future treatment
strategies.
Living donors with HCV infection and viremia should preferably receive appropriate treat‐
ment prior to donation, since the duration of therapy is short and it leads to sustained SVR [79].
On the other hand, prior to donation the transplant team should carefully consider and explain
to the donor the risk for developing HCV‐associated renal disease or diabetes mellitus in the
future.
Based on the aforementioned data, the policy of transplanting a kidney from an anti‐HCV–
positive donor to an anti‐HCV–positive recipient is considered to be a safe approach with good
clinical outcomes in the long term. In any case prior to receiving an allograft, the HCV‐infected‐
transplant candidate should be informed in detail about the HCV status of the donor, the risk
of super‐infection or other complications, the data regarding patient and graft survival, as well
as the new treatment options.
7. Impact of HCV infection on posttransplant outcomes
Hepatitis C adversely affects the survival of both patients and grafts. Numerous, predomi‐
nantly retrospective cohort studies report inferior 10‐year survival rate of HCV‐positive
patients in comparison to uninfected kidney recipients [80–82]. Age at transplantation and the
presence of anti‐HCV antibodies were independently associated with patient survival [81].
However, a serious limitation of these studies is that histological data regarding the severity
of hepatic disease pretransplantation were not available in the majority of them.
A recent meta‐analysis of 18 observational trials that included 133,530 renal allograft recipients
revealed an increased rate of all‐cause mortality in HCV‐positive patients after transplantation,
regardless of the year of transplantation and thus the immunosuppressive regimen that was
used, the country of origin or the number of patients. The main causes of death were cirrhosis
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and hepatocellular cancer. It is worth noting that hepatic disease developed late after trans‐
plantation. Cardiovascular mortality and cardiovascular disease were also more prevalent in
this study group [83]. Additional extrahepatic causes of morbidity and mortality were new
onset diabetes after transplantation (NODAT), de novo and recurrent glomerular diseases
(mainly de novo type I membranoproliferative GN), and sepsis [84–86].
The abovementioned studies demonstrated also that graft survival is decreased in seropositive
patients posttransplantation. More specifically, the meta‐analysis by Fabrizi et al. showed that
the adjusted relative risk of graft loss in these patients compared to those who are not infected
was 1.76 [83]. Allograft failure has been attributed to the aforestated morbidity factors, namely
diabetes and glomerulonephritides, as well as to the occurrence of transplant glomerulopathy
and chronic allograft injury [83–87].
8. Therapy
Treatment of patients infected with HCV comprises the traditional approach with interferon
and ribavirin, as well as novel regimens, interferon‐a‐free that consist of the direct‐acting
antiviral agents. Therapeutic regimens aim at the elimination of the virus. The viral load, based
on HCV RNA quantification in serum, must be undetectable (10–15 IU/ml) 12 weeks after the
end of treatment (SVR).
8.1. Traditional therapy
In the past decade, interferon and ribavirin were considered to be the cornerstone of HCV
antiviral treatment. Nonetheless, these drugs were associated with considerable toxicity. More
specifically, the use of interferon after kidney transplantation induced acute kidney injury,
episodes of rejection resistant to steroid therapy, and graft loss [88, 89]. Therefore, before 2013
transplant candidates could only be treated prior to transplantation as the KDIGO guidelines
recommended, with the exception of patients with fibrosing cholestatic hepatitis [53]. How‐
ever, the Dialysis Outcomes Practice Patterns Study demonstrated that only a minority of ESRD
patients on dialysis were treated for HCV [90]. Among 4589 HCV‐positive HD patients who
were observed from 1996 to 2011, only 48 (1%) were treated for HCV, whereas among the subset
of patients waiting on the list for transplantation, only 3.7% were treated for HCV. The reasons
for this approach were as follows:
• The use of ribavirin in this patient population aggravated anemia that was already present
due to chronic kidney disease.
• Pegylated interferon‐α (PegIFN‐α) as monotherapy resulted in poor outcomes, with SVR
30–35% [91].
• Addition of ribavirin in low doses increased the SVR to 55% after 6 months, but also
increased side effects [92].
• A substantial percentage of patients (18–30%) dropped out of therapy.
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Nevertheless, HCV clearance when achieved was maintained posttransplantation in the vast
majority of patients despite the use of immunosuppression [93].
8.2. Novel therapeutic agents
Thorough understanding of the HCV structure, replication mechanism, and cell cycle has led
to the development of the DAAs. These drugs are small molecules that target nonstructural
(NS) viral proteins and inhibit HCV replication. Four classes of DAAs exist, namely NS3/4A
protease inhibitors (PIs) simeprevir, paritaprevir, and grazoprevir, NS5B nucleoside polymer‐
ase inhibitors (NPIs) and non‐nucleoside polymerase inhibitors (NNPIs) sofosbuvir and
dasabuvir, respectively, and NS5A inhibitors ledipasvir, daclatasvir, ombitasvir, and elbasvir
[94].
The introduction of these new agents has modernized the therapeutic ammunition and has
radically changed the treatment of patients with HCV infection; ongoing trials are expected to
prove the safety and efficacy of DAAs in patients with impaired renal function and ESRD and
establish proper dosing regimens. Besides the spectacular effectiveness of these drugs (SVR
over 95%) in patients who had not received prior therapy [95], another important issue is the
improved tolerance to treatment, due to reduced treatment duration and fewer side effects.
Different combinations of DAAs are administered based on the different HCV genotypes
(Table 1).
Genotype 1α kαι 1b
PegIFN‐α, RBV, and Sofosbuvir
PegIFN‐α, RBV, and Simeprevir
Sofosbuvir and Ledipasvir
Ritonavir, Paritaprevir
Ombitasvir and Dasabuvir
Sofosbuvir and Simeprevir or Daclatasvir
Grazoprevir, Elbasvir ± Ribavirin
Genotype 4
PegIFN‐α, RBV, and Sofosbuvir
PegIFN‐α, RBV, and Simeprevir
Sofosbuvir and Ledipasvir
Ritonavir, Paritaprevir, Ombitasvir
Sofosbuvir and Simeprevir or Daclatasvir
Grazoprevir, Elbasvir ± Ribavirin
Genotype 2
PegIFN‐α, RBV, and Sofosbuvir
Sofosbuvir and RBV
Sofosbuvir and Daclatasvir
Genotype 5
PegIFN‐α, RBV, and Sofosbuvir
Sofosbuvir and Ledipasvir
Genotype 3
PegIFN‐α, RBV, and Sofosbuvir
Sofosbuvir and Daclatasvir
Genotype 6
PegIFN‐α, RBV, and Sofosbuvir
Sofosbuvir and Ledipasvir
Table 1. Treatment recommendation (EASL 2015) for chronic hepatitis C patients without liver cirrhosis.
The first studies that evaluated the effectiveness of DAAs excluded patients with estimated
glomerular filtration rate (eGFR) less than 30 ml/min/1.73m2, patients on dialysis, and renal‐
transplant recipients. It is worth noting that sofosbuvir is contraindicated for patients with
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eGFR <30 ml/min/1.73m2 and for dialysis patients [94, 95]. Therefore, treatment options for this
study group with HCV infection from genotypes 2, 3, 5, and 6 of HCV are limited, because all
regimens include sofosbuvir. Severe, urgent cases should receive treatment after careful expert
consultation. On the other hand, results are very promising for patients with genotypes 1 and
4 in comparison with the general population. Ruby‐I is a single‐arm multicenter study, in which
20 patients with HCV genotype 1 and CKD stage 4,5 or in dialysis were given ombitasvir co‐
formulated with paritaprevir and ritonavir, administered with dasabuvir for 12 weeks. Patients
with HCV genotype 1a infection also received ribavirin (n:13), whereas those with genotype1b
infection did not (n:7). The majority of patients, 90%, achieved the primary end point which
was SVR 12 weeks after the end of treatment (SVR12). One patient did not achieve an SVR12
because of a relapse and another one died from causes not related to treatment. The most
common adverse event was anemia (69%) due to ribavirin treatment, which led to drug
discontinuation in nine cases [96]. C‐Surfer is a multicenter, phase 3, randomized study of
safety and observational study of efficacy regarding the combination of grazoprevir and
elbasvir (both approved by the Food and Drug Administration (FDA) and wait to be approved
by the European Medicines Agency (EMA) in 2016) for patients with genotype 1 infection and
stage 4–5 CKD. The treatment group consisted of 111 patients, who received grazoprevir and
elbasvir for 12 weeks. The results were remarkable. The SVR12 was 99%, with only one patient
relapsing, whereas the drugs were well tolerated with minor adverse events that did not lead
to drug discontinuation [97].
The use of interferon‐free treatment regimens is of major importance in renal transplantation
because it eliminates the risk of acute allograft rejection and subsequent graft loss. An
important question that arises is when is the proper timing of treatment, pre‐ or post trans‐
plantation? The introduction of DAAs permits us to exceed the narrow timeframes before
transplantation and treat our patients after transplantation. Thus, we have the advantage of
using allografts from HCV‐positive donors for recipients willing to accept them. This practice
minimizes the time on the waiting list and subsequently the time on dialysis and all its
deleterious effects as we have already mentioned, but it cannot be applied in small countries
such as Greece with extremely long waiting time on the list. On the other hand, treatment with
DAAs prior to transplantation may offer the advantage of increasing the overall survival of
patients by diminishing the risk of hepatic and extrahepatic complications especially severe,
evolving liver disease, glomerulonephritis and NODAT. Another important issue to consider
when deciding the timing of treatment is the virus genotype. Eradication of the virus in patients
infected with genotype 1 or 4 is plausible before transplantation, since sofosbuvir‐free
regimens are available.
In renal transplantation, the DAAs are used according to the guidelines applied to the general
population and the liver‐transplant recipients. Until 2016, there were no data to guide the use
of these agents in kidney transplant patients and to demonstrate their efficacy and safety to
this subpopulation of patients. The policy of many transplant centers, including ours, is that
all kidney‐transplant patients with chronic HCV infection and eGFR >30 ml/min/1.73m2 receive
appropriate therapy with a new, interferon‐free antiviral regimen based on the detected
genotype (Table 1). The dose of DAAs is not adjusted when eGFR is greater than 30 ml/min/
Advances in Treatment of Hepatitis C and B234
1.73m2. Ribavirin is not recommended with eGFR <30 ml/min/1.73m2 although it has been used
in patients after renal transplantation with a close monitoring of hemoglobin levels [98].
Of great importance are the drug‐drug interactions between the DAAs and the immunosup‐
pressive agents and the mandatory dose adjustments (Table 2).
Green: No significant interaction is expected.
Orange: Possible interaction which requires close monitoring, changing the dosage, and/or drug‐delivery time.
Red: Avoid concomitant use of drugs.
This table is based on data by the University of Liverpool on the site http://www.hep‐druginteractions.org (University of
Liverpool). For additional drug‐drug interactions and for a more extensive range of drugs, detailed pharmacokinetic
interaction data, and dosage adjustments, refer to the abovementioned website.
Table 2. Interactions between immunosuppressive drugs and DAA agents.
Since 2016, several studies have emerged. Kamar et al. tried to assess the efficacy and safety of
an interferon‐free regiment based on sofosbuvir. Twenty‐five renal‐transplant recipients with
HCV infection (19/25 Genotype 1, 2/25 Genotype 2, 1/25 Genotype 3, 3/25 Genotype 4) received
various combinations of sofosbuvir with other agents; ribavirin (n:3), daclatasvir (n:4),
simeprevir (n:6), simeprevir and ribavirin (n:1), ledipasvir (n:9), ledipasvir and ribavirin (n:1),
pegylated interferon and ribavirin (n:1). At week 12, an impressive SVR of 100% was recorded.
During therapy, no significant adjustments in the dose of immunosuppressive drugs were
required and kidney function remained stable [109]. However, after virus clearance, trough
levels of tacrolimus decreased without any dose change. It is already known that HCV infection
alters the pharmacokinetics of CNIs and results in increased drug exposure [99]. Therefore,
we must be cautious after HCV clearance and adjust the dose of CNIs accordingly. A case series
study of 20 HCV‐infected kidney recipients (85% Genotype 1, 15% Genotype 2) who were
treated off‐label with sofosbuvir in combination with simeprevir (n:9), ribavirin (n:3), ledipas‐
vir (n:7), and daclatasvir (n:1) demonstrated a sustained virological response of 100% at week
12 and it was maintained for a short median follow‐up period of 8.6 months [100].
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These impressive results show that the efficacy and safety of DAAs in renal transplant
recipients is comparable with the general population. It remains to be determined if viral
clearance after transplantation will improve long‐term patient and kidney‐allograft outcomes.
The optimal timing of HCV therapy (posttransplantation or pretransplantation) has not clearly
been determined. Taking into account that based on clinical trials the DAAs will be available
for patients with eGFR <30/ml/min/1.73m2 in the near future, treating these patients before
transplantation may prevent posttransplantation complications and improve the overall
outcomes. For the time being, ESRD patients infected with HCV Genotypes 2, 3, 5, 6 can be
treated with DAAs only after transplantation or when it is absolutely obligatory in life‐
threatening conditions.
9. Immunosuppression in HCV‐positive kidney transplant recipients
Immunosuppression may increase hepatitis C viral proliferation after transplantation and thus
accelerate the evolution of hepatic damage [101]. Information regarding the use of immuno‐
suppressive drugs in seropositive allograft recipients comes mostly from liver transplantation,
as well as from the experience in the field of oncology‐hematology. Large, prospective studies
examining the effect of immunosuppressive drugs in HCV‐seropositive recipients are lacking.
However, the total amount of induction and maintenance immunosuppression may play an
important role in the reactivation of the virus post transplantation.
10. Immunosuppressive agents
10.1. Rituximab
The use of anti‐CD20 monoclonal antibody rituximab has been reported in a small number of
seven HCV‐positive patients after kidney transplantation. It was not related to the recurrence
of the infection in a follow‐up period of 19 months [102]. Larger studies in the field of hema‐
tology have shown a high incidence of hepatic flares in HCV‐seropositive patients following
treatment with Rituximab for lymphoma [103].
10.2. Induction therapy
Data from the Scientific Registry of Transplant Recipients (SRTRs) demonstrated that induction
therapy, with polyclonal or monoclonal antibodies, has been associated with a lower risk of
death. This finding could probably be attributed to lower rejection rates in patients receiving
induction treatment [104]. Anti‐CD3 monoclonal antibody OKT3, however, has been associ‐
ated with recurrence of HCV in liver transplantation [105]. It is therefore avoided in HCV‐
infected patients after transplantation. On the other hand, the administration of the polyclonal
antibody antithymocyte globulin (ATG) as induction therapy in 104 HCV‐infected kidney‐
transplant patients did not induce viral replication [106], a finding that was confirmed by
subsequent studies [107]. Contradictory data exist regarding monoclonal anti‐IL2 antibodies,
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such as daclizumab. A single‐center study in a small number of patients showed that therapy
with daclizumab is followed by faster progression of liver fibrosis compared to ATG [108].
Large studies based on data from the United Network for Organ‐Sharing UNOS base indicate
that liver‐transplant recipients with chronic HCV infection exhibit satisfactory graft and
patient survival after receiving induction with daclizumab [109, 110].
10.3. Corticosteroids (CS)
High pulses of corticosteroids can cause up to 100 times increase of the viral load, but this has
only been demonstrated in liver transplantation [107]. Although rapid steroid discontinuation
leads to lower rates of diabetes and HCV recurrence, it has been associated with worst
outcomes in liver transplantation [111, 112]. In the aforementioned study by Luan et al., in a
total of 3708 HCV‐positive kidney transplant patients, mortality rates were similar between
those who received CS and those who did not [104].
10.4. Calcineurin inhibitors (CNIs)
In vitro studies have shown that cyclosporine may have an antiviral effect by suppressing HCV
replication and the expression of proteins [113]. Moreover, cyclosporine is less diabetogenic
in comparison with tacrolimus. However, in a cohort of 71 patients with HCV infection
posttransplantation, liver fibrosis and viral replication were similar regardless of the CNI
used [114]. Additionally, data from the Scientific Registry of Transplant Recipients (SRTR)
[104] did not confer a survival advantage of cyclosporine over tacrolimus in renal allograft
recipients.
10.5. Antimetabolites
MPAs appear to be safe in HCV‐seropositive individuals after kidney transplantation. Notably,
MMF administration was related to a reduced risk of death (hazard ratio (HR): 0.77, p: 0.005)
in the study by Luan et al., implying a possible advantageous effect of the drug in renal
recipients with chronic HCV infection [104].
10.6. Mammalian target of rapamycin (mTOR) inhibitors
Data regarding the use of mTOR inhibitors in transplant patients with HCV infection are
limited. Sirolimus was associated with decreased evolution of hepatic fibrosis and cell
proliferation in vitro, in an animal model of hepatic fibrosis [115]. This finding was not
confirmed in a small cohort study of HCV‐infected kidney recipients, where switch from CNI
to sirolimus was not followed by lower viral load [116].
In conclusion, almost all immunosuppressive agents can be used in HCV‐positive renal
recipients. As in the case of HBV, the most important issue is the total level of immunosup‐
pression, which should be kept as low as possible based on the specific conditions of trans‐
plantation and the immunological profile of the recipient. Close monitoring of HCV RNA is
mandatory.
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11. In summarizing the existing evidence about kidney transplantation
and HCV
• The prevalence of hepatitis C in patients with ESRD presents great variation worldwide and
is correlated with the time on dialysis.
• Kidney transplantation is the choice of therapy for HCV‐infected patients with ESRD.
• Mortality is lower among patients who undergo kidney transplantation compared to those
remaining on the waiting list.
• Liver biopsy should be performed in all HCV‐infected renal transplant candidates.
• Systematic screening for HCV should be routinely done in all ESRD patients. Dialysis units
with a high prevalence of HCV should preferably test all patients for HCV RNA, regardless
of the presence of anti‐HCV antibodies.
• Well‐compensated cirrhosis is not a contraindication to kidney transplantation.
• Renal transplant recipients with chronic HCV infection have lower patient and allograft
survival post transplantation compared with noninfected renal transplant recipients.
• Major causes of mortality in HCV‐infected renal transplant recipients are cirrhosis and
hepatocellular cancer. Additional causes of morbidity following kidney transplantation are
de novo and recurrent and glomerular diseases and NODAT.
• Transplantation of a renal allograft from an HCV‐infected donor may cause HCV infection
to the recipient.
• All potential kidney donors, deceased and living, should be evaluated for the risk of HCV
infection based on blood tests, medical history, and lifestyle habits.
• Kidneys from HCV‐positive donors are donated to anti‐HCV–positive recipients.
• Interferon should not be administered in renal transplant recipients with chronic HCV
infection because it is associated with rejection episodes and graft loss.
• We suggest the following approach regarding antiviral treatment in HCV‐infected renal
allograft recipients:
◦ All patients with eGFR >30 ml/min/1.73 m2 should receive a new, interferon‐free antiviral
regimen based on the virus genotype.
◦ Patients with eGFR <30 ml/min/1.73 m2 should not be treated with sofosbuvir. Treatment
options for genotypes 2, 3, 5, and 6 of HCV are limited. In severe conditions, treatment
should be discussed with experts.
◦ In the case of HCV genotype 1 or 4, the combination grazoprevir‐elbasvir can be admin‐
istered.
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◦ Potential drug‐drug interactions of antivirals with immunosuppressive agents present an
important issue in selecting the appropriate immunosuppressive regimen after kidney
transplantation.
◦ Immunosuppressive agents can safely be used in HCV‐positive renal recipients with close
monitoring of HCV RNA and minimization of immunosuppression.
In conclusion, the development of direct‐acting antiviral agents (DAAs) may change the
natural history of HCV infection in renal allograft recipients. Randomized, prospective trials
are expected to prove the safety and efficacy, as well as the optimal dose of DAAs in patients
with impaired renal function, ESRD, and kidney transplantation.
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